Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr James Callery

Dr James Callery

James Callery

Research Physician

James Callery is a British medical doctor who has worked as a Research Physician within the Malaria Department at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand since 2017.

At MORU James has worked as co-investigator and Research Physician on the TACT-CV study, a multicentre therapeutic efficacy and safety trial in Southeast Asia, comparing artemether-lumefantrine (ACT) with artemether-lumefantrine plus amodiaquine (Triple ACT) for the treatment of uncomplicated falciparum malaria. He has been running and monitoring the study sites in Cambodia whilst working in close collaboration with colleagues across the Greater Mekong Subregion (GMS).

With the development and spread of multi-drug resistant malaria parasites, this novel combination therapy could play an important role in the efforts to eliminate malaria from the GMS.

Since 2018, James has also coordinated large public engagement projects in Northeastern Cambodia. These events aim to engage the local community with malaria prevention and other health awareness campaigns.

James’ main research interest is focussed on the development and evaluation of novel malaria intervention strategies to aid elimination efforts in the GMS. The TACT-CV study will be completed in early 2020 and James has already begun work on a new clinical trial evaluating ACTs as malaria prophylaxis in Cambodian forest-goers.